Interactions between ibuprofen and antihypertensive drugs : Incidence and clinical relevance in dental practice by Salort Llorca, Cesar et al.
E717
Med Oral Patol Oral Cir Bucal. 2008 Nov 1;13(11):E717-21.                                                                                        Ibuprofen – Antihypertensive drug interactions in dental practice                                                                            Med Oral Patol Oral Cir Bucal.  2008 Nov 1;13(11):E717-21.                                                                                                                       Ibuprofen – Antihypertensive drug interactions in dental practice
Interactions between ibuprofen and antihypertensive drugs: 
Incidence and clinical relevance in dental practice
César Salort Llorca 1, María Paz Mínguez Serra 2, Francisco Javier Silvestre Donat 3
(1) Service of Pharmacy. Mutua de Terrassa Hospital (Barcelona)
(2) Stomatology Unit. Doctor Peset University Hospital (Valencia)
(3) Department of Stomatology. Valencia University Medical and Dental School. Head of the Stomatology Unit. Doctor Peset 
University Hospital (Valencia), Spain
Correspondence:
Prof. F.J. Silvestre Donat
Unidad de Estomatología
Hospital Dr. Peset. Consultas externas
C/ Juan de Garay s/n
46017 – Valencia (Spain)
E-mail: francisco.silvestre@uv.es
Received: 27/04/2008
Accepted: 31/08/2008 Salort-Llorca C, Mínguez-Serra MP, Silvestre-Donat FJ. Interactions 
between ibuprofen and antihypertensive drugs: Incidence and clinical 
relevance in dental practice. Med Oral Patol Oral Cir Bucal. 2008 Nov 
1;13(11):E717-21.
© Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946
http://www.medicinaoral.com/medoralfree01/v13i11/medoralv13i11p717.pdf
Abstract
It has been well documented in the literature that ibuprofen interacts with different groups of antihypertensive 
drugs (beta-adrenergic blockers, alpha-adrenergic blockers, diuretics and angiotensin-converting enzyme inhibitors), 
reducing their antihypertensive activity. The mechanism of action of ibuprofen involves inhibition of the enzyme 
cyclooxygenase, thereby inhibiting the synthesis of inflammatory prostaglandins and vasodilatory prostaglandins that 
increase renal blood flow and thus favor the excretion of water and sodium. More than five days of treatment with 
both drugs are normally required for the interaction to manifest. Although the changes in blood pressure resulting 
from this interaction are typically small, some patients can experience substantial elevations in both systolic and 
diastolic blood pressure. It has been estimated that the avoidance of minor changes in systolic pressure in patients 
with osteoarthritis subjected to treatment with nonsteroidal antiinflammatory drugs would avoid over 30,000 deaths 
due to myocardial infarction, and over 2000 deaths due to coronary disease, in the United States alone.
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Introduction
The management of pain is common practice in dental 
patients. In many cases patients visit the dental clinic due 
to persistent pain, while in other situations treatment is 
required for acute postoperative pain. The substances 
commonly used in dental practice for the control of pain 
are nonsteroidal antiinflammatory drugs (NSAIDs), and 
particularly ibuprofen (1-4). 
Ibuprofen is an NSAID offering good control of pain in 
dental practice, with a favorable benefit/risk ratio. Howe-
ver, its use is not without risks in the form of adverse 
reactions (gastroduodenal ulcers) and interactions with 
other drugs (5). 
The antiinflammatory properties of ibuprofen are due to 
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inhibition of the activity of the enzyme cyclooxygenase, 
which plays a key role in the synthesis of prostaglandins 
(6). These prostaglandins in turn favor inflammatory 
processes on one hand, and the modulation of vasodila-
tation, glomerular filtration, tubular secretion of sodium 
and water, and the renin-angiotensin system on the other 
(7).
Arterial hypertension (AHT) is very common in Spain, 
with a prevalence of 25-35% in the adult population (8-10). 
The condition is more common in the elderly, and many 
individuals are unaware that they have hypertension. These 
data illustrate the magnitude of the problem, and indicate 
that a considerable number of patients requiring dental 
treatment are using antihypertensive drugs.
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A broad range of drugs have been show to be clinically 
effective in treating AHT (Table 1). Depending on the 
mechanism of  action involved, mention can be made 
of beta-adrenergic blockers, alpha-adrenergic blockers, 
angiotensin-converting enzyme inhibitors (ACEIs), angio-
tensin II receptor antagonists (ARAIIs), diuretics, calcium 
channel blockers, and vasodilators (though the efficacy of 
the latter is less clear). 
Drug interactions occur when the effects of a given drug 
are modified as a result of the presence of some other 
drug substance in the body. Such interactions may be 
pharmacokinetic or pharmacodynamic. The former are 
related to drug transit through the body, while pharmaco-
dynamic interactions are attributable to the mechanisms 
of action of the implicated drugs. The consequences of 
drug interaction may prove deleterious both as a result of 
antagonism of the affected drug (with a loss of efficacy) 
and as a consequence of synergism or reinforcement of 
drug action – thereby generating a risk of toxicity.
The present study reviews and describes the clinically 
relevant interactions of the analgesic ibuprofen with the 
different drugs used to treat AHT, since such substances 
are widely used by patients seen in the dental clinic. To 
this effect, a Medline search was made based on the key 
words ibuprofen, antihypertensive drugs and interaction 
- limiting the search to those studies found in the english 
literature and conducted in human subjects. Among the 
articles thus obtained, we selected those best suited to the 
objectives of our study.
Results
Raddack and Deck conducted a three-week, parallel-group 
clinical trial involving 41 patients with a mean age of 52 
years receiving treatment with at least two antihypertensive 
drugs, and distributed into three groups (ibuprofen 600 
mg every 12 hours, paracetamol or placebo). The results 
showed the ibuprofen group to experience a significant 
increase in blood pressure in comparison with the other 
two groups (11).
The literature reports the case of a patient in which the 
antihypertensive effect of the beta-blocker pindolol was 
cancelled by ibuprofen (12). However, in a randomized 
comparative study, the concomitant administration of 
propanolol and ibuprofen 400 mg every 6 hours exerted 
no significant effect upon blood pressure (13).
Koopmans et al. (14) carried out an open-label trial of 
8 patients to quantify the increase in blood pressure in 
subjects treated with the diuretic hydrochlorothiazide 50 
mg daily concomitant to four weeks of ibuprofen 400 mg 
every 8 hours, diclofenac 25 mg three times a day, or su-
lindac 200 mg every 12 hours. A significant rise in systolic 
blood pressure was observed in the patients treated with 
ibuprofen, though the authors concluded that these three 
NSAIDs can be used without risk in patients treated with 
hydrochlorothiazide – provided careful blood pressure 
monitorization is carried out on introducing NSAID 
treatment.
Gurwitz et al. (15) conducted a randomized, double-blind 
and placebo-controlled clinical trial of 22 patients over 
65 years of age. All the subjects were receiving antihyper-
tensive treatment with the diuretic hydrochlorothiazide, 
and were subjected to alternating four-week periods of 
treatment with ibuprofen 600 mg every 8 hours or placebo. 
The authors concluded that in elderly patients treated with 
hydrochlorothiazide, ibuprofen induces a significantly 
greater increase in blood pressure than placebo, and that 
ibuprofen may negatively affect high blood pressure con-
trol in elderly individuals.
The interaction of ibuprofen with the diuretic furosemide 
has been described in two isolated and independent cases 
involving ibuprofen doses of 400 mg every 8 hours and 
600 mg four times a day, respectively (16,17). In com-
parison, the interaction of furosemide with the NSAID 
indomethacin has been well documented in different 
studies (18,19).
The administration of  ibuprofen in 90 hypertensive 
patients treated with angiotensin-converting enzyme 
inhibitors induced a blood pressure rise in 16.6% of the 
subjects (20). Likewise, the case has been reported of an 
elderly woman in whom the administration of ibuprofen 
attenuated the antihypertensive effects of captopril (21). 
However, the administration of ibuprofen 800 mg three 
times a day in 17 black women receiving fosinopril / hydro-
chlorothiazide had no effect upon blood pressure (22).
Houston et al. (23) conducted a randomized, double-blind 
and placebo-controlled clinical trial with a duration of 
three weeks to evaluate the effects of ibuprofen, naproxen 
and placebo in patients treated with verapamil – a calcium 
channel blocker – at a dose of 240-480 mg/day. A total 
of 162 patients between 18-75 years of age were included 
in the study. The authors concluded that the addition of 
ibuprofen or naproxen to antihypertensive treatment with 
verapamil did not increase blood pressure, and that vera-
pamil offers advantages as antihypertensive treatment in 
patients requiring NSAIDs during long periods of time. 
However, that same year Minuz et al. (24) published a 
study of 12 hypertensive patients treated with amlodipi-
ne – another calcium channel blocker – at a dose of 10 
mg/day, in which concomitant treatment with ibuprofen 
400 mg every 8 hours for three days effectively increased 
blood pressure.
In a metaanalysis of the effects of NSAIDs upon blood 
pressure, Johnson et al. (25) found the rise in blood pres-
sure to be greater in the patients receiving antihypertensive 
treatment. These results were reproduced in the metaanaly-
sis published by Pope et al. (26). In the study of Johnson 
et al., the NSAIDs inducing the greatest blood pressure 
increments were found to be piroxicam, indomethacin and 
ibuprofen, while the metaanalysis of Pope et al. identified 
naproxen and indomethacin as the drugs inducing the 
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THERAPEUTIC GROUP DRUG BRAND NAME
Beta-adrenergic blockers Atenolol Blokium, Neatenol, Tenormin, GDP*
 Bisoprolol Emconcor, Emcoretic, Euradal, GDP*
 Carvedilol Coropres, GDP*
 Labetalol Trandate
 Metoprolol Beloken, Lopresor
 Nadolol Corgard, Solgol
 Nebivolol Lobivon, Nebilet, Nebilox, Silostar
 Propanolol Sumial
 Sotalol Sotapor, GDP*
Calcium channel blockers Amlodipine Amlor, Astudal, Kerniox, Norvas, GDP*
 Diltiazem Angiodrox, Lacerol, Masdil, Tilker, GDP*
 Felodipine Fensel, Perfudal, Plendil, GDP*
 Lacidipine Lacimen, Lacipil, Motens
 Lercanidipine Lercadip, Lerzam, Zanidip
 Manidipine Artedil
 Nicardipine Dagan, Lecibral, Lincil, Vasonase, GDP*
 Nifedipine Adalat, Dilcor, Pertensal, GDP
 Nimodipine Admon, Brainal, Calnit, Nimotop, GDP*
 Verapamil Manidon
Angiotensin-converting enzyme inhibitors Captopril Capoten, Cesplon, Dilabar, Garanil, GDP
 Enalapril Acetensil, Crinoren, Dabonal, GDP*
 Fosinopril Fositens, Tenso Stop, Tensocardil, GDP
 Lisinopril Doneka, Iricil, Prinivil, Zestril, GDP*
 Perindopril Coversil
 Quinapril Acuprel, Ectren, Lidaltrin, GDP*
 Ramipril Acovil, Carasel, GDP*
Angiotensin II receptor antagonists Candesartan Atacand, Blopress, Parapres
 Eprosartan Futuran, Navixen, Regulaten, Tevetens
 Irbesartan Aprovel, Karvea, Karvezide
 Losartan Cozaar, Fortzaar
 Olmesartan Ixia, Olmetec, Openwas
 Telmisartan Micardis, Pritor
 Valsartan Diovan, Kalpress, Miten, Vals
Alpha-adrenergic blockers Doxazosin Carduran, Doximax, Progandol, GDP*
 Prazosin Minipres
 Urapidil Elgadil
Diuretics Amiloride Ameride, Diuzine
 Bumetanide Fordiuran
 Chlorthalidone Higrotona, Aldoleo
 Eplerenone Elecor, Inspra
 Spironolactone Aldactone, Spirometon, GDP*
 Furosemide Seguril, GDP*
 Hydrochlorothiazide Esidrex, Hidrosaluretil
 Indapamide Extur, Tertensif, GDP*
 Piretanide Perbilen
 Teclothiazide Quimodril
 Torasemide Dilutol, Tadegan, GDP*
 Triamterene Salidur
Xipamide Diurex
Tabla 1. Antihypertensive drugs marketed in Spain.
* GDP: generic drug product. GDPs include the name of the drug substance in the brand designation.
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greatest pressure increases – no statistically significant 
association being found between ibuprofen and a rise in 
blood pressure. However, it should be mentioned that in 
the study published by Pope et al. the mean age of the 
patients included in the metaanalysis was 46 years.
 
Discussion
Interactions between ibuprofen and antihypertensive 
drugs clinically manifest when ibuprofen is used in chronic 
treatments. Normally more than 4-5 days of treatment 
with both drugs are needed for interactions to manifest 
(7,23,27). In dental practice, ibuprofen is usually prescri-
bed for short periods of time – thus allowing use of the 
drug for the control of acute dental pain in patients on 
antihypertensive medication, provided such treatment is 
not prolonged for more than 4-5 days (7).
However, even with short periods of  treatment, inte-
ractions are possible - particularly in more susceptible 
individuals such as the elderly, patients with congestive 
heart disease, and hypertensive patients with low renin 
concentrations.
Although the changes in blood pressure produced by such 
interactions are usually small (5-6 mmHg), some patients 
may experience substantial both systolic and diastolic 
blood pressure elevations. It has been estimated that by 
avoiding even small changes in systolic pressure among 
patients with osteoarthritis treated with NSAIDs, it would 
be possible to avoid over 30,000 deaths due to myocardial 
infarction, and over 2000 deaths due to coronary disease, 
in the United States alone (27). In other words, the blood 
pressure increment that may result from such drug inte-
ractions increases the risk of acute myocardial infarction 
and of coronary disease among hypertensive patients by 
45-67% (7,23) and 15%, respectively (23).
Not all antihypertensive drugs interact in the same way 
with ibuprofen. Interaction has been described in sufficient 
detail in the case of beta-adrenergic blockers, diuretics 
and angiotensin-converting enzyme inhibitors, though 
ibuprofen also appear to interact with alpha-adrenergic 
blockers. However, no such interactions appear to occur 
with the calcium channel blockers, since their antihyper-
tensive activity is not dependent upon prostaglandin action 
(7). Still, some cases of interaction have been reported, 
and caution is advised until further information becomes 
available. On the other hand, there have been no repor-
ted cases of interaction with the angiotensin II receptor 
antagonists, which have been introduced more recently in 
therapeutic practice.
The interaction of ibuprofen with the above commented 
antihypertensive drugs is extendable to other NSAIDs, 
though it seems that aspirin (acetylsalicylic acid) and 
sulindac produce no such interactions (28). Likewise, the 
analgesics paracetamol and codeine do not appear to 
induce interactions (7), though controversy persists on 
this point.
It would be good clinical practice to always specify the 
duration of treatment when prescribing ibuprofen, in order 
to prevent chronic use of the medication from increasing 
the risks of both adverse reactions and interactions with 
other drugs.
Patients subjected to antihypertensive treatment should 
undergo closer blood pressure monitorization at the start 
of analgesic treatment with ibuprofen and other nonste-
roidal antiinflammatory drugs.
While the use of ibuprofen for the treatment of acute pain 
offers great advantages in routine clinical practice, due 
consideration is required of those situations ibuprofen 
may not be the best choice.
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